Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

This study has been terminated.

First Received: June 5, 2002 Last Updated: June 23, 2005 History of Changes

Sponsored by:	M.D. Anderson Cancer Center
Information provided by:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00038883

Purpose

High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.

Condition	Intervention
Leukemia, Lymphocytic, Chronic Leukemia, Lymphocytic, Acute Lymphoma, Low-Grade Lymphoma, T-Cell Lymphoma, B-Cell	Drug: Campath-1H

MedlinePlus related topics: Cancer Leukemia, Adult Acute Leukemia, Adult Chronic Leukemia, Childhood Lymphoma

Drug Information available for: Campath Alemtuzumab

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title:	Campath-1H Snd Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

Further study details as provided by M.D. Anderson Cancer Center:

Estimated Enrollment:	142
Study Start Date:	April 2001

Eligibility

Ages Eligible for Study:	15 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Patients with CLL, ALL, low grade Lymphoma, B and T cell Lymphoma of the intermediate and high grade (if not eligible for autologous transplant) CD52 expression of >20% by flow cytometry.
Patients in relapse after conventional treatment.
Patients with an HLA-identical or one-antigen mismatched sibling, or matched unrelated donor.
Patients previously exposed to Campath-1H treatment response. Patient must be at least 2 months or later from the last dose of Campath-1H.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00038883

Locations

United States, Texas
MDAnderson Cancer Center
Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

More Information

No publications provided

Study ID Numbers:	ID99-410
Study First Received:	June 5, 2002
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00038883 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by M.D. Anderson Cancer Center:

Lymphoid Malignancies
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Low grade Lymphoma
B and T cell Lymphoma of the intermediate and high grade

Study placed in the following topic categories:

Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunoproliferative Disorders
Lymphoma, B-Cell
Leukemia
Lymphatic Diseases
Chronic Lymphocytic Leukemia
B-cell Lymphomas
Leukemia, Lymphocytic, Chronic, B-Cell

Alemtuzumab
Lymphoma, T-Cell
Leukemia, B-cell, Chronic
Leukemia, B-Cell
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Lymphoma
Acute Lymphoblastic Leukemia

Additional relevant MeSH terms:

Leukemia, Lymphoid
Immunoproliferative Disorders
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Immune System Diseases
Antineoplastic Agents
Pharmacologic Actions
Lymphoma, B-Cell
Leukemia
Lymphatic Diseases

Neoplasms
Leukemia, Lymphocytic, Chronic, B-Cell
Therapeutic Uses
Alemtuzumab
Lymphoma, T-Cell
Leukemia, B-Cell
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Lymphoma

ClinicalTrials.gov processed this record on May 07, 2009